000304996 001__ 304996
000304996 005__ 20251005022950.0
000304996 0247_ $$2doi$$a10.3238/arztebl.m2025.0102
000304996 0247_ $$2pmid$$apmid:40560375
000304996 0247_ $$2altmetric$$aaltmetric:180497650
000304996 037__ $$aDKFZ-2025-01987
000304996 041__ $$aEnglish
000304996 082__ $$a610
000304996 1001_ $$0P:(DE-He78)7e1ae89aec6f303c09c45a12ebb31d7d$$aKlimeck, Leon$$b0$$eFirst author$$udkfz
000304996 245__ $$aFecal Occult Blood Tests for Colorectal Cancer Screening in Routine Medical Care: A Longitudinal Analysis From Germany.
000304996 260__ $$aKöln$$bDt. Ärzte-Verl.$$c2025
000304996 3367_ $$2DRIVER$$aarticle
000304996 3367_ $$2DataCite$$aOutput Types/Journal article
000304996 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759230429_31256
000304996 3367_ $$2BibTeX$$aARTICLE
000304996 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304996 3367_ $$00$$2EndNote$$aJournal Article
000304996 500__ $$a#EA:C070#LA:C070#
000304996 520__ $$aWell-organized programs for colorectal cancer (CRC) screening with fecal occult blood testing (FOBT) can reach over 70% of the eligible population. FOBT was opportunistic in Germany up to 2019. Until March 2025, it was offered annually to persons aged 50 to 54 and twice per year to persons aged 55 and above. Cross-sectional analyses revealed only moderate annual adherence rates, but it remained unclear whether the tests were used regularly by a small share of the population or sporadically by a large share of the population.We used anonymized data from BARMER, a German statutory health insurance carrier, to study trends in adherence to annual FOBT screening among persons aged 50 to 54 over the years 2010-2022. The data pertained to 945 214 men and women who were born in the period 1960-1968.Despite the offer of annual screening, only 22.5% of men and 55.1% of women had at least one FOBT between the ages of 50 and 54. Only 0.1% of men and 1.8% of women used the screening annually as offered. The use of screening has declined even further in recent years. CRC was found in 1.4% of follow-up colonoscopies in both men and women.The opportunistic mode of offering annual FOBT for CRC screening in Germany is highly ineffective, as most of the eligible population did not have even a single test from age 50 to age 54.
000304996 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000304996 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304996 650_2 $$2MeSH$$aHumans
000304996 650_2 $$2MeSH$$aColorectal Neoplasms: diagnosis
000304996 650_2 $$2MeSH$$aColorectal Neoplasms: epidemiology
000304996 650_2 $$2MeSH$$aOccult Blood
000304996 650_2 $$2MeSH$$aGermany: epidemiology
000304996 650_2 $$2MeSH$$aMale
000304996 650_2 $$2MeSH$$aFemale
000304996 650_2 $$2MeSH$$aMiddle Aged
000304996 650_2 $$2MeSH$$aEarly Detection of Cancer: statistics & numerical data
000304996 650_2 $$2MeSH$$aEarly Detection of Cancer: methods
000304996 650_2 $$2MeSH$$aLongitudinal Studies
000304996 650_2 $$2MeSH$$aMass Screening: statistics & numerical data
000304996 650_2 $$2MeSH$$aAged
000304996 650_2 $$2MeSH$$aCross-Sectional Studies
000304996 7001_ $$0P:(DE-HGF)0$$aHeisser, Thomas$$b1
000304996 7001_ $$aHennig, Beata$$b2
000304996 7001_ $$aGraf, Christian$$b3
000304996 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b4$$udkfz
000304996 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author$$udkfz
000304996 773__ $$0PERI:(DE-600)2406159-1$$a10.3238/arztebl.m2025.0102$$gVol. 122, no. 17$$n17$$p455-460$$tDeutsches Ärzteblatt international$$v122$$x1866-0452$$y2025
000304996 909CO $$ooai:inrepo02.dkfz.de:304996$$pVDB
000304996 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7e1ae89aec6f303c09c45a12ebb31d7d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304996 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000304996 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000304996 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000304996 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000304996 9141_ $$y2025
000304996 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDTSCH ARZTEBL INT : 2022$$d2025-01-07
000304996 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000304996 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000304996 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000304996 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000304996 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000304996 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000304996 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bDTSCH ARZTEBL INT : 2022$$d2025-01-07
000304996 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000304996 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000304996 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000304996 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000304996 980__ $$ajournal
000304996 980__ $$aVDB
000304996 980__ $$aI:(DE-He78)C070-20160331
000304996 980__ $$aI:(DE-He78)HD01-20160331
000304996 980__ $$aUNRESTRICTED